
In a fifth aspect, there is provided a compound as defined above, for use in the treatment or prevention of a central nervous system disorder selected from the group of anxiety, schizophrenia, migraine, depression, epilepsy, behavioral and psychological symptoms of dementia, major depressive disorder, treatment resistant depression, bipolar depression, generalised anxiety disorder, post-traumatic stress disorder, bipolar mania, substance abuse and mixed anxiety and depression.

In a sixth aspect, there is provided ~~a compound as defined above in combination with an orthosteric agonist of mGluR2 for use in the treatment or prevention of a disorder as defined above.~~ use of the compound or the pharmaceutical composition as defined above in the manufacture of a medicament for the treatment or prevention of a central nervous system disorder selected from the group of anxiety disorders, psychotic disorders, personality disorders, substance related disorders, eating disorders, mood disorders, migraine, epilepsy or convulsive disorders, childhood disorders, cognitive disorders, neurodegeneration, neurotoxicity and ischemia.

In a seventh aspect, there is provided a process for preparing a pharmaceutical composition as defined above, characterized in that a pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective amount of a compound as defined above.

In an eighth aspect, there is provided ~~a product comprising~~
~~(a) a compound as defined above; and~~
~~(b) an mGluR2 orthosteric agonist,~~
~~as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of a central nervous system disorder selected from the group of anxiety disorders, psychotic disorders, personality disorders, substance-related disorders, eating disorders, mood disorders, migraine, epilepsy or convulsive disorders, childhood disorders, cognitive disorders, neurodegeneration, neurotoxicity and ischemia.~~ use of the compound as defined above in the manufacture of a medicament for the treatment or prevention of a central nervous system disorder selected from the group of anxiety, schizophrenia, migraine, depression, epilepsy, behavioral and psychological symptoms of dementia, major depressive disorder, treatment resistant depression, bipolar depression, generalised anxiety disorder, post-traumatic stress disorder, bipolar mania, substance abuse and mixed anxiety and depression.



1'-[8-chloro-3-(2,2,2-trifluoroethyl)-1,2,4-triazolo[4,3-a]pyridin-7-yl]-3,3-dimethyl-spiro[isobenzofuran-1(3H),4'-piperidine]

or a pharmaceutically acceptable salt thereof or a solvate thereof.

10. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 9 and a pharmaceutically acceptable carrier or excipient.

11. A compound according to any one of claims 1 to 9 for use as a medicament.

12. A compound according to any one of claims 1 to 9 or a pharmaceutical composition according to claim 10 for use in the treatment or prevention of a central nervous system disorder selected from the group of anxiety disorders, psychotic disorders, personality disorders, substance related disorders, eating disorders, mood disorders, migraine, epilepsy or convulsive disorders, childhood disorders, cognitive disorders, neurodegeneration, neurotoxicity and ischemia.

13. The compound according to any one of claims 1 to 9, for use in the treatment or prevention of a central nervous system disorder selected from the group of anxiety, schizophrenia, migraine, depression, epilepsy, behavioral and psychological symptoms of dementia, major depressive disorder, treatment resistant depression, bipolar depression, generalised anxiety disorder, post-traumatic stress disorder, bipolar mania, substance abuse and mixed anxiety and depression.

14. ~~A compound according to any one of claims 1 to 9 in combination with an orthosteric agonist of mGluR2 for use in the treatment or prevention of a disorder as cited in claim 12 or 13.~~ Use of the compound according to any one of claims 1 to 9 or the pharmaceutical composition according to claim 10 in the manufacture of a medicament for the treatment or prevention of a central nervous system disorder selected from the group of anxiety disorders, psychotic disorders, personality disorders, substance related disorders, eating disorders, mood disorders, migraine, epilepsy or convulsive disorders, childhood disorders, cognitive disorders, neurodegeneration, neurotoxicity and ischemia.

15. A process for preparing a pharmaceutical composition as defined in claim 10, characterized in that a pharmaceutically acceptable carrier is intimately mixed with a therapeutically effective amount of a compound as defined in any one of claims 1 to 9.

16. ~~A product comprising~~
~~(a) a compound as defined in any one of claims 1 to 9; and~~
~~(b) a mGluR2 orthosteric agonist,~~
~~as a combined preparation for simultaneous, separate or sequential use in the treatment or prevention of a central nervous system disorder selected from the group of anxiety disorders, psychotic disorders, personality disorders, substance related disorders, eating disorders, mood disorders, migraine, epilepsy or convulsive disorders, childhood disorders, cognitive disorders, neurodegeneration, neurotoxicity and ischemia.~~
Use of the compound according to any one of claims 1 to 9 in the manufacture of a medicament for the treatment or prevention of a central nervous system disorder selected from the group of anxiety, schizophrenia, migraine, depression, epilepsy, behavioral and psychological symptoms of dementia, major depressive disorder, treatment resistant depression, bipolar depression, generalised anxiety disorder, post-traumatic stress disorder, bipolar mania, substance abuse and mixed anxiety and depression.